e-therapeutics Past Earnings Performance
Past criteria checks 0/6
e-therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 22% per year.
Key information
-25.6%
Earnings growth rate
-6.4%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 22.0% |
| Return on equity | -36.5% |
| Net Margin | -2,957.6% |
| Last Earnings Update | 31 Jul 2023 |
Recent past performance updates
Recent updates
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Jan 05
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Sep 13e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Mar 27We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Jul 07We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn
Oct 28Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?
Mar 21We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Feb 14Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?
Jan 10
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
Dec 06Revenue & Expenses BreakdownBeta
How e-therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 23 | 0 | -10 | 4 | 9 |
| 30 Apr 23 | 0 | -9 | 4 | 8 |
| 31 Jan 23 | 0 | -8 | 3 | 7 |
| 31 Oct 22 | 0 | -9 | 4 | 7 |
| 31 Jul 22 | 0 | -9 | 4 | 7 |
| 30 Apr 22 | 0 | -9 | 4 | 6 |
| 31 Jan 22 | 0 | -8 | 4 | 6 |
| 31 Oct 21 | 1 | -6 | 3 | 5 |
| 31 Jul 21 | 1 | -4 | 2 | 4 |
| 30 Apr 21 | 1 | -4 | 2 | 3 |
| 31 Jan 21 | 0 | -4 | 2 | 3 |
| 31 Oct 20 | 0 | -4 | 2 | 2 |
| 31 Jul 20 | 0 | -3 | 2 | 2 |
| 30 Apr 20 | 0 | -3 | 2 | 2 |
| 31 Jan 20 | 0 | -2 | 1 | 2 |
| 31 Oct 19 | 0 | -3 | 1 | 2 |
| 31 Jul 19 | 0 | -3 | 1 | 3 |
| 30 Apr 19 | 0 | -4 | 1 | 3 |
| 31 Jan 19 | 0 | -4 | 1 | 4 |
| 31 Oct 18 | 0 | -4 | 2 | 4 |
| 31 Jul 18 | 0 | -5 | 2 | 4 |
| 30 Apr 18 | 0 | -5 | 2 | 5 |
| 31 Jan 18 | 0 | -5 | 2 | 5 |
| 31 Oct 17 | 0 | -7 | 2 | 6 |
| 31 Jul 17 | 0 | -8 | 2 | 7 |
| 30 Apr 17 | 0 | -11 | 2 | 9 |
| 31 Jan 17 | 0 | -13 | 2 | 11 |
| 31 Oct 16 | 0 | -13 | 2 | 11 |
| 31 Jul 16 | 0 | -12 | 2 | 11 |
| 30 Apr 16 | 0 | -11 | 2 | 11 |
| 31 Jan 16 | 0 | -9 | 2 | 10 |
| 31 Oct 15 | 0 | -8 | 2 | 10 |
| 31 Jul 15 | 0 | -8 | 2 | 9 |
| 30 Apr 15 | 0 | -8 | 2 | 9 |
| 31 Jan 15 | 0 | -8 | 2 | 9 |
| 31 Oct 14 | 0 | -7 | 2 | 8 |
| 31 Jul 14 | 0 | -7 | 2 | 7 |
| 30 Apr 14 | 0 | -6 | 2 | 6 |
| 31 Jan 14 | 0 | -5 | 1 | 5 |
| 31 Oct 13 | 0 | -5 | 1 | 5 |
Quality Earnings: ETX is currently unprofitable.
Growing Profit Margin: ETX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ETX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare ETX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: ETX has a negative Return on Equity (-36.53%), as it is currently unprofitable.